Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
RLMD Stock Price Chart Interactive Chart >
RLMD Price/Volume Stats
| Current price | $4.60 | 52-week high | $38.68 |
| Prev. close | $4.60 | 52-week low | $4.34 |
| Day low | $4.34 | Volume | 806,100 |
| Day high | $4.66 | Avg. volume | 501,952 |
| 50-day MA | $13.91 | Dividend yield | N/A |
| 200-day MA | $21.42 | Market Cap | 138.46M |
Relmada Therapeutics, Inc. (RLMD) Company Bio
Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.
Latest RLMD News From Around the Web
Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and nine months ended September 30, 2022. The Company will host a conference call today, Thursday, November 10, at 4:30 PM Eastern Time/1:30 PM Pacific Time. |
Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2022 after the market close on Thursday, November 10, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, November 10, 2022. |
We Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & MoreRegulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week. |
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression StudyRelmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news. |
RLMD Price Returns
| 1-mo | -27.67% |
| 3-mo | N/A |
| 6-mo | -76.61% |
| 1-year | -72.83% |
| 3-year | -89.05% |
| 5-year | 59.72% |
| YTD | -79.58% |
| 2021 | -29.75% |
| 2020 | -17.77% |
| 2019 | 747.83% |
| 2018 | 53.33% |
| 2017 | -31.19% |
Loading social stream, please wait...